Microbot Medical Inc (MBOT)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$1.14+4.59%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · MBOT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Exhibit 99.1 Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter Revenue increased by more than 100% over prior fiscal quarter, driven by repe…
Stated in 2 of 2 supplied quarters. Management reported: “Exhibit 99.1 Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter Revenue increased by more than 100% over prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market Release in mid-April.” “|| ● | Broadened its sales footprint to eight sales territories compared to four sales territories at the end of March 2026, allowing the Company to be on track to have 12 territories across the U.S. by year-end.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 0 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 29% of the time over the next year (vs 52% for the rest of the cohort, n=10118).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Exhibit 99.1 Microbot Medical® Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter Revenue increased by more than 100% over prior fiscal quarter, driven by repe…”
“Exhibit 99.1 Microbot Medical Successfully Transitions to Commercial Operations as It Records Revenue Resulting from Its Limited Market Release During the First Quarter of 2026 Recent transition to t…”
|| ● | Having successfully completed the Limited Market Release in April 2026, and with its associated costs partially being accounted for in the second quarter of 2026, coupled with other cost reduc…
Stated in 1 of 2 supplied quarters. Management reported: “|| ● | Having successfully completed the Limited Market Release in April 2026, and with its associated costs partially being accounted for in the second quarter of 2026, coupled with other cost reduction activities which are being implemented, the Company believes it will substantially reduce its cost of revenue which increased in the three-month period ended June 30, 2026 compared to the three-month period ended March 31, 2026.” “At the same time, we continue to implement cost reduction initiatives to lower the cost of revenues.”
“|| ● | Having successfully completed the Limited Market Release in April 2026, and with its associated costs partially being accounted for in the second quarter of 2026, coupled with other cost reduc…”
|| ● | Achieved a significant regulatory milestone as Israel became the second jurisdiction, and the first outside of the U.S., to grant marketing clearance for the LIBERTY System.
Stated in 1 of 2 supplied quarters. Management reported: “|| ● | Achieved a significant regulatory milestone as Israel became the second jurisdiction, and the first outside of the U.S., to grant marketing clearance for the LIBERTY System.” “To ensure the Company has the capacity to meet current and future demand, it recently entered into an agreement to establish a second manufacturing site, positioning the Company for potential long-term margin expansion as volumes scale.”
“|| ● | Achieved a significant regulatory milestone as Israel became the second jurisdiction — and the first outside of the U.S. — to grant marketing clearance for the LIBERTY System.”
Develop international commercial infrastructure and readiness for LIBERTY, including progress toward European market entry and use of newly obtained marketing clearance.
Build a second manufacturing facility to increase production capacity and enable future cost reductions and margin improvements.
Over the trailing year it converted 1.03x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
26 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-04.